drugset
drugset / Trial / NCT04609020

Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial Treatment

NCT04609020 ↗

Phase 4 Completed 64 enrolled Allergan
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to quantify the psychological, social, and emotional impact of comprehensive aesthetic treatment with a portfolio of the Sponsor's products by measuring the change in subject's satisfaction with facial appearance from baseline (before any treatment) to the final study visit

Timeline

Start
2023-02-15
Primary completion
2024-05-10
Completion
2024-05-10

Outcome

Met primary endpoint

registry analysis (superiority test); HArmonyCA; p <0.0001; Mean Difference (Final Values) 46.6; t-test, 1 sided; NCT04609020 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic — —

Indications

No indication recorded.